Terameprocol in Treating Patients With Recurrent High Grade Glioma

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) of terameprocol given orally on days 1-5 every 28 days in patients with high grade glioma. (Part 1) II. To evaluate terameprocol tumor to plasma ratios in resected high grade gliomas following 5 days of oral terameprocol administration. (Part 2) III. To assess the maximum duration of terameprocol that can be safely administered on a continuous basis. (Part 3) SECONDARY OBJECTIVES: I. Characterize the plasma pharmacokinetic (PK) of oral terameprocol. II. Evaluate the toxicities of oral terameprocol. III. Assess progression-free survival. IV. Estimate overall survival. V. Assess tumor response. TERTIARY OBJECTIVES: I. Assess the contribution of cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) genotypes on the variability of oral terameprocol pharmacokinetics. OUTLINE: This is a dose-escalation study. Patients receive terameprocol orally (PO) once daily (QD) on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days, every 2 months for 2 years, and then every 6 months thereafter.